123I-MIBG Imaging: Patient Preparation and Technologist’s Role

Journal of Nuclear Medicine Technology

Randall C. Thompson¹  S. Seth Van Vickle¹ 

[1] Saint Luke’s Mid America Heart Institute and Saint Luke’s Cardiovascular Consultants, Kansas City, MissouriSaint Luke’s Mid America Heart Institute and Saint Luke’s Cardiovascular Consultants, Kansas City, Missouri Saint Luke’s Mid America Heart Institute and Saint Luke’s Cardiovascular Consultants, Kansas City, Missouri

关键词: ¹²³I-MIBG;    cardiac sympathetic imaging;    cardiac denervation;    techniques for MIBG imaging;   

DOI  :  10.2967/jnmt.115.158394

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The radiopharmaceutical 123I-metaiodobenzylguanidine (MIBG) was approved by the Food and Drug Administration in March 2013 for the assessment of myocardial sympathetic innervation in the evaluation of patients with heart failure and an ejection fraction of no more than 35%. Almost any well-equipped nuclear medicine or nuclear cardiology laboratory can perform this test, although there is a need for special attention to patient preparation, dose calibration, and proper timing of the image acquisition. This article reviews the role of the nuclear medicine technologist and some practical aspects of cardiac sympathetic 123I-MIBG imaging of which the laboratory team needs to be mindful.

【 授权许可】

Unknown